# Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct06782932/  
OnCo record `nct06782932` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of balstilimab and cyclophosphamide in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.

## Summary

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06782932 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 38 participants, started 2025-05-27 and due to reach its primary completion in 2028-12. Interventions recorded: AGEN2373; Balstilimab; Cyclophosphamide; GVAX; AGEN2373 (RP2D); Balstilimab; mKRASvax. Conditions listed: Pancreatic Cancer. Primary outcome: Dose Limiting Toxicities in Phase I participants; Number of participants experiencing Grade 3 or Higher study drug-related toxicities; Number of participants who form Intratumoral tertiary lymphoid structures (TLS). Pancreatic eligibility wording from the registry: "* Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06782932
- Phase: 1/2
- Setting: A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT06782932: https://clinicaltrials.gov/study/NCT06782932

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06782932.json